Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the FDA classification notes, litigation updates, and segment revenue buried in MiMedx’s 250-page reports can drain an analyst’s day. The company’s focus on placental allografts and its history of regulatory inquiries make every footnote matter—yet the disclosures are technical and scattered across multiple forms.
Stock Titan solves that problem. Our AI reads each submission the moment it posts to EDGAR and serves plain-English takeaways, turning a dense MiMedx annual report 10-K simplified into a two-minute brief. Need the latest MiMedx quarterly earnings report 10-Q filing or an alert when a director buys shares? You’ll find it here alongside AI-generated red-flag summaries. Key filings appear in real time, including:
- "MiMedx insider trading Form 4 transactions" – instant view of every executive trade
- "MiMedx 8-K material events explained" – concise notes on product recalls, clinical milestones, or leadership changes
- "MiMedx proxy statement executive compensation" – breakdown of incentive plans tied to wound-care growth
Our platform links each data point back to the source so you can verify detailed footnotes on Purion process patents, pending reimbursement appeals, or R&D spending trends. Whether you’re understanding MiMedx SEC documents with AI, seeking MiMedx earnings report filing analysis, or monitoring MiMedx Form 4 insider transactions real-time, Stock Titan keeps every disclosure searchable, summarized, and always current—helping investors compare graft sales growth, track patent litigation outcomes, and assess cash runway without wading through hundreds of pages.
MiMedx Group Chief Commercial Officer Kimberly Maersk-Moller reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 24, 2025. The insider disposed of 12,034 shares of Common Stock at a price of $5.96 per share through a tax withholding transaction (Code F).
Key Transaction Details:
- The shares were withheld for payment of tax liability upon vesting of restricted stock units
- Following the transaction, Maersk-Moller directly owns 295,282 shares of Common Stock
- The transaction was executed under a Form 4 filing obligation pursuant to Section 16(a) of the Securities Exchange Act
This routine tax-related share withholding suggests the vesting of previously awarded restricted stock units, rather than an open market sale decision by the insider.
MiMedx Group Director Todd Newton received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing his direct beneficial ownership to 412,771 shares.
Key details of the transaction:
- The grant is exempt under Rule 16b-3 as part of non-employee director compensation
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Transaction was filed via Form 4 on June 28, 2025
- Filing was signed by William F. Hulse as attorney-in-fact
This routine compensation grant reflects standard board member equity incentives and demonstrates continued alignment between director and shareholder interests.
MiMedx Group Director M. Kathleen Behrens received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing her total direct holdings to 212,771 shares.
Key details of the transaction:
- The grant is part of non-employee director compensation
- Transaction is exempt under Rule 16b-3
- Shares will vest at the earlier of 12 months or the next annual shareholder meeting
- Form 4 was filed by William F. Hulse as attorney-in-fact
This routine compensation grant demonstrates continued alignment between director and shareholder interests through equity-based compensation. The transaction represents approximately 13.4% increase in the director's direct holdings in the company.
MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.
The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:
- 12 months from grant date
- The next annual meeting of shareholders
The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.
MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share. This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.
Following the transaction, Hawkins now beneficially owns a total of 204,018 shares directly. The restricted stock grant will vest upon the earlier of 12 months or the next annual meeting of shareholders.
Key Transaction Details:
- Transaction Type: Acquisition (Form 4)
- Stock Type: Common Stock
- Transaction Value: Approximately $185,100
- Ownership Form: Direct
- Filing Date: June 28, 2025
MiMedx Group director Cato T. Laurencin acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing their total direct holdings to 181,923 shares.
The transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. Key details about the grant:
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Transaction was filed as a Form 4 pursuant to Section 16(a) of Securities Exchange Act
- The acquisition was reported as a direct ownership transaction
This insider transaction indicates ongoing compensation practices for board members and alignment with shareholder interests through equity-based compensation.
FAQ
What is the current stock price of Mimedx Group (MDXG)?
What is the market cap of Mimedx Group (MDXG)?
